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Summary 
The diagnosis and treatment of infectious diseases are today increasingly challenged by the emergence 
of difficult-to-manage situations, such as infections associated with medical devices and invasive 
fungal infections, especially in immunocompromised patients. The aim of this thesis was to address 
these challenges by developing new strategies for eradication of biofilms of difficult-to-treat 
microorganisms (treatment, part 1) and investigating innovative methods for microbial detection and 
antimicrobial susceptibility testing (diagnosis, part 2).  
The first part of the thesis investigates antimicrobial treatment strategies for infections caused by two 
less investigated microorganisms, Enterococcus faecalis and Propionibacterium acnes, which are 
important pathogens causing implant-associated infections. The treatment of implant-associated 
infections is difficult in general due to reduced susceptibility of bacteria when present in biofilms. 
We demonstrated an excellent in vitro activity of gentamicin against E. faecalis in stationary growth-
phase and were able to confirm the activity against “young” biofilms (3 hours) in an experimental 
foreign-body infection model (cure rate 50%). The addition of gentamicin improved the activity of 
daptomycin and vancomycin in vitro, as determined by time-kill curves and microcalorimetry. In vivo, 
the most efficient combination regimen was daptomycin plus gentamicin (cure rate 55%). Despite a 
short duration of infection, the cure rates were low, highlighting that enterococcal biofilms remain 
difficult to treat despite administration of newer antibiotics, such as daptomycin.   
By establishing a novel in vitro assay for evaluation of anti-biofilm activity (microcalorimetry), we 
demonstrated that rifampin was the most active antimicrobial against P. acnes biofilms, followed by 
penicillin G, daptomycin and ceftriaxone. In animal studies we confirmed the anti-biofilm activity of 
rifampin (cure rate 36% when administered alone), as well as in combination with daptomycin (cure 
rate 63%), whereas in combination with vancomycin or levofloxacin it showed lower cure rates (46% 
and 25%, respectively). We further investigated the emergence of rifampin resistance in P. acnes in 
vitro. Rifampin resistance progressively emerged during exposure to rifampin, if the bacterial 
concentration was high (108 cfu/ml) with a mutation rate of 10-9. In resistant isolates, five point 
mutations of the rpoB gene were found in cluster I and II, as previously described for staphylococci 
and other bacterial species.  
The second part of the thesis describes a novel real-time method for evaluation of antifungals against 
molds, based on measurements of the growth-related heat production by isothermal microcalorimetry. 
Current methods for evaluation of antifungal agents against molds, have several limitations, especially 
when combinations of antifungals are investigated. We evaluated the activity of amphotericin B, 
triazoles (voriconazole, posaconazole) and echinocandins (caspofungin and anidulafungin) against 
Aspergillus spp. by microcalorimetry. The presence of amphotericin B or a triazole delayed the heat 
production in a concentration-dependent manner and the minimal heat inhibition concentration 
(MHIC) was determined as the lowest concentration inhibiting 50% of the heat produced at 48 h. Due 
to the different mechanism of action echinocandins, the MHIC for this antifungal class was 
determined as the lowest concentration lowering the heat-flow peak with 50%. Agreement within two 
2-fold dilutions between MHIC and MIC or MEC (determined by CLSI M38A) was 90% for 
amphotericin B, 100% for voriconazole, 90% for posaconazole and 70% for caspofungin. We further 
evaluated our assay for antifungal susceptibility testing of non-Aspergillus molds. As determined by 
microcalorimetry, amphotericin B was the most active agent against Mucorales and Fusarium spp., 
whereas voriconazole was the most active agent against Scedosporium spp. Finally, we evaluated the 
activity of antifungal combinations against Aspergillus spp. Against A. fumigatus, an improved 
activity of amphotericin B and voriconazole was observed when combined with an echinocandin. 
Against A. terreus, an echinocandin showed a synergistic activity with amphotericin B, whereas in 
combination with voriconazole, no considerable improved activity was observed.  
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Resumé 
Aujourd'hui, les problèmes des maladies infectieuses concernent l'émergence d'infections difficiles à 
traiter, telles que les infections associées aux implants et les infections fongiques invasives chez les 
patients immunodéprimés. L'objectif de cette thèse était de developper des stratégies pour l'éradication 
des biofilms bactériens (partie 1), ainsi que d'étudier des méthodes innovantes pour la détection 
microbienne, pour l’établissement de nouveaux tests de sensibilité (partie 2). 
Le traitement des infections associées aux implants est difficile car les biofilms bactériens peuvent 
résister à des niveaux élevés d'antibiotiques. A ce jour, il n’y a pas de traitement optimal défini contre 
des infections causées par des bactéries de prévalence moindre telles que Enterococcus faecalis ou 
Propionibacterium acnes. Dans un premier temps, nous avons démontré une excellente activité in 
vitro de la gentamicine sur une souche de E. faecalis en phase stationnaire de croissance Nous avons 
ensuite confirmé l’activité de la gentamicine sur un biofilm précoce en modèle expérimental animal à 
corps étranger avec un taux de guérison de 50%. De plus, les courbes de bactéricidie ainsi que les 
résultats de calorimétrie ont prouvé que l’ajout de gentamicine améliorait l’activité in vitro de la 
daptomycine, ainsi que celle de la vancomycine. In vivo, le schéma thérapeutique le plus efficace était 
l’association daptomycine/gentamicine avec un taux de guérison de 55%.  
En établissant une nouvelle méthode pour l’évaluation de l’activité des antimicrobiens vis-à-vis de 
micro-organismes en biofilm, nous avons démontré que le meilleur antibiotique actif sur les biofilms à 
P. acnes était la rifampicine, suivi par la penicilline G, la daptomycine et la ceftriaxone. Les études 
conduites en modèle expérimental animal ont confirmé l’activité de la rifampicine seule avec un taux 
de guérison 36%. Le meilleur schéma thérapeutique était au final l’association 
rifampicine/daptomycine avec un taux de guérison 63%. Les associations de rifampicine avec la 
vancomycine ou la levofloxacine présentaient des taux de guérisons respectivement de 46% et 25%.  
Nous avons ensuite étudié l’émergence in vitro de la résistance à la rifampicine chez  P. acnes. Nous 
avons observé un taux de mutations de 10-9. La caractérisation moléculaire de la résistance chez les 
mutant-résistants a mis en évidence l’implication de 5 mutations ponctuelles dans les domaines I et II  
du gène rpoB. Ce type de mutations a déjà été décrit au préalable chez d’autres espèces bactériennes, 
corroborant ainsi la validité de nos résultats.  
La deuxième partie de cette thèse décrit une nouvelle méthode d’évaluation de l’efficacité des 
antifongiques basée sur des mesures de microcalorimétrie isotherme. En utilisant un microcalorimètre, 
la chaleur produite par la croissance microbienne peut être mesurée en temps réel, très précisément.   
Nous avons évalué l’activité de l’amphotéricine B, des triazolés et des échinocandines sur différentes 
souches de Aspergillus spp. par microcalorimétrie. La présence d’amphotéricine B ou de triazole 
retardait la production de chaleur de manière concentration-dépendante. En revanche, pour les 
échinochandines, seule une diminution le pic de « flux de chaleur » a été observé. La concordance 
entre la concentration minimale inhibitrice de chaleur (CMIC) et la CMI ou CEM (définie par CLSI 
M38A), avec une marge de 2 dilutions, était de 90% pour l’amphotéricine B, 100% pour le 
voriconazole, 90% pour le pozoconazole et 70% pour la caspofongine. La méthode a été utilisée pour 
définir la sensibilité aux antifongiques pour d’autres types de champignons filamenteux. Par 
détermination microcalorimétrique, l’amphotéricine B s’est avéré être l’agent le plus actif contre les 
Mucorales et les Fusarium spp.. et  le voriconazole le plus actif contre les Scedosporium spp. 
Finalement, nous avons évalué l’activité d’associations d’antifongiques vis-à-vis de Aspergillus spp. 
Une meilleure activité antifongique était retrouvée avec l’amphotéricine B ou le voriconazole lorsque 
ces derniers étaient associés aux échinocandines vis-à-vis de A. fumigatus. L’association 
échinocandine/amphotéricine B a démontré une activité antifongique synergique vis-à-vis de A. 
terreus, contrairement à l’association échinocandine/voriconazole qui ne démontrait aucune 
amélioration significative de l’activité antifongique. 
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PART I. 
Evaluation of new treatment strategies for implant-
associated infections caused by difficult-to diagnose and 
difficult-to-treat microorganisms. 
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Chapter 1. General introduction. 
Bacterial biofilms. 
  
Bacteria can exist as single cells, also called planktonic, or in sessile aggregates, which is 
commonly referred to as a biofilm growth mode. The definition of a bacterial biofilm, as for 
medical microbiology, is a “coherent cluster of bacterial cells imbedded in a matrix, which are 
more tolerant to most antimicrobials and the host defense, than planktonic bacterial cells” [1]. 
The life cycle of a biofilm, illustrated in figure 1, can be divided into three main stages as 
follows; bacterial adhesion to an abiotic or biotic surface and aggregation of cells (1), 
bacterial proliferation and biofilm maturation, including production of the extracellular matrix 
(2), and detachment and dispersal of planktonic bacteria (3) [2].  
 
 
 
 
The biofilm matrix, composed by extracellular polymeric substances (EPS), immobilizes the 
bacteria and keeps them in close proximity, allowing cell-to-cell communication, also known 
as quorum sensing [3]. Through quorum sensing, bacteria secrete and detect autoinducer 
molecules, in a cell-density dependent manner, which will influence their behavior, including 
production of the EPS and virulence factors [4]. In addition, the matrix creates a scavenging 
system, serving as a nutrient supply and protecting bacteria from the host defense and 
antimicrobial agents [3, 5]. A biofilm is a dynamic system which maintains balance through 
growth and dispersal. Dispersal of planktonic cells, either as single cells or microcolonies, is 
Figure 1. The biofilm life cycle. A biofilm 
starts to form when bacteria attach to a surface, 
(1); the biofilm matures through growth of the 
bacterial cells and production of the 
extracellular matrix (2); eventually planktonic 
bacteria can detach and disperse from the 
biofilm (3).                                      
From: biofilmbook.hypertextbookshop.com 
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important in a medical perspective since bacteria can spread from the infection site to the 
whole body [1]. 
The biofilm mode of growth represents a survival strategy, and the biofilm bacteria can be up 
to 1000-fold more resistant to antimicrobials than their planktonic counterparts [6]. However, 
once bacteria detach from the biofilm they generally become susceptible again, which 
suggests that the antimicrobial tolerance in biofilm is not due to common resistance 
mechanisms, such as efflux pumps, target mutations or modifying enzymes [6]. Several 
hypotheses behind the mechanism of tolerance in bacterial biofilms exist [7]. Studies show 
that the penetration of antimicrobials into the biofilm can be delayed by interactions with 
components of the biofilm matrix and that some antimicrobials can become even fully 
inactivated by chelating enzymes [5]. Even though most antimicrobials are capable to 
successfully penetrate the matrix they might be unable to kill metabolically inactive bacteria, 
located in the nutrient- and oxygen-deprived layers of the biofilm [5]. Another type of 
bacteria contributing to the antimicrobial resistance are the so-called persister cells, 
representing a sub-population of spore-like cells present in a non-growing stationary phase 
[8]. Persister cells can escape most antimicrobial agents targeting cellular processes, such as 
cell wall synthesis, DNA replication and translation, taking place only in physiologically 
active bacteria. 
Implant-associated infections. 
  
Due to a higher median age of the population, suffering from degenerative diseases, and an 
emerging technology in the field on medical devices, implants are increasingly used to 
improve or replace parts or functions of the human body [9]. One of the most successful and 
frequently used types of implant is the prosthetic joint. Only in Switzerland, around 20 000 
hip and 16 000 knee prosthesis are implanted every year (Swiss Implant Registry, www.siris-
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implant.ch). Infections associated with implants are rare, ranging from 1-5% depending on 
type of device, but are difficult to diagnose and to treat [10]. The treatment is associated with 
high costs, due to the need of several surgical interventions and prolonged hospital stay. An 
implant can be infected exogenously, during surgery or wound healing, or hematogenously 
via the bloodstream any time after implantation [10]. 
Microbiology. 
 
Prosthetic-joint infections can be classified according to time of manifestation. Early and 
delayed infections of exogenous origin manifest within 3 months and between 3 months and 2 
years after implantation, respectively, whereas late infections manifest after 2 years [9]. Early 
infections are in general caused by highly virulent bacteria, such as Staphylococcus aureus 
and Escherichia coli, whereas delayed infections are mainly caused by low-virulent bacteria, 
such as S. epidermidis and Propionibacterium acnes. S. aureus causes most of the late 
infections of hematogenous origin [10]. The distribution of species isolated from prosthetic-
joint infections is presented in figure 2. In around 11% of cases no microorganism is detected 
[11].  
 
 
 
 
 
Figure 2. Species distribution of bacteria isolated from prosthetic-joint infections. Adapted from [11]. 
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During the last decades, most research in the field of biofilm and implant-associated 
infections has been focusing on staphylococci. Consequently, there has been important 
progress, both in the understanding of staphylococcal biofilm biogenesis, and in improvement 
and optimization of antimicrobial treatment of staphylococcal biofilm infections. Regarding 
the less frequently found species, such as enterococci and anaerobes, including P. acnes, the 
optimal treatment regimens have not yet been defined. 
Enterococcus faecalis. 
 
Enterococci are opportunistic pathogens increasingly recognized as the cause of healthcare-
acquired infections, especially in endocarditis, bacteremia and urinary tract infections [12]. 
They are Gram-positive facultative anaerobic cocci naturally colonizing the gastrointestinal 
and female genital tract and the oral cavity [12]. E. faecalis is the most common entercoccal 
species, accounting for 80 - 90% of infections, followed by E. faecium, which is more often 
associated with antimicrobial resistance [12]. In comparison with other Gram-positive 
bacteria, enterococci are relatively low virulent, but can persist in harsh conditions, such as 
low pH, high salt concentrations and extreme temperatures, especially when present in 
biofilm [13].  
Enterococcal biofilms have been detected on a wide range of medical devices, including 
orthopedic implants, intravascular catheters, biliary stents, silicone gastrostomy devices and 
ocular lenses [14]. In E. faecalis, several proteins have been identified to play important roles 
in the biofilm biogenesis (figure 3). In the early steps of biofilm formation, surface proteins, 
such as enterococcal surface protein (Esp) and adhesion to collagen by E. faecalis (Ace) 
contribute to adhesion of bacteria, whereas aggregation substance (AS) promotes the 
aggregation of replicating bacteria [15]. In addition, a surface pili composed by proteins 
coded by the epb locus (Endocarditis and biofilm associated pili) has been demonstrated as 
important for the biofilm formation of E. faecalis [16]. When the bacterial density is 
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sufficient, the quorum sensing locus frc (E. faecalis regulator) will activate the secretion of 
proteases that together with Esp and Ace will lead to maturation of the biofilm [14]. Another 
gene that was shown to be essential for successful infection in mice, including biofilm 
formation on inert surfaces and invasion of phagocytes, is the bopD (biofilm on plastic 
surface D) gene [13]. From the mature biofilm cytolysins and proteases, such as gelatinase, 
are secreted and can cause tissue damage by lysing host cells, including polymorphonuclear 
leukocytes [14]. 
 
 
Enterococci cause subacute infections of prosthetic joints that are particularly difficult to treat 
and associated with high failure rates [9]. The reasons for treatment failure are not entirely 
clear, but could be explained by virulence factors associated with biofilm formation described 
above, and the unavailability of antimicrobial agents active against enterococcal biofilms [9]. 
A few studies demonstrated activity of the staphylococcal anti-biofilm agent rifampin against 
enterococcal biofilms in vitro, in combination with ciprofloxacin and linezolid [17] and in 
vivo, in combination with tigecycline [18]. However, based on clinical experience of 
Figure 3. Factors implicated in the biofilm formation of E. faecalis. Proteins involved in the bacterial 
attachment includes Esp (enterococcal surface protein), Ace (adhesion to collagen by E. faecalis), AS 
(aggregation substance) and epb (endocarditis and biofilm associated pili).In the mature biofilm quorum 
sensing is mediated by the frc (E. faecalis regulator) locus. From the biofilm proteases and cytolysin can be 
secreted causing tissue damage. Adapted from . 
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treatment failure associated with the use of the drug, rifampin is currently not recommended 
for treatment of enterococcal implant-associated infections [9]. In addition, enterococci may 
acquire genes encoding resistance against β-lactams, glycopeptides, aminoglycosides and 
oxazolidinones, which further complicates the treatment of infections [12].  
Propionibacterium acnes. 
 
P. acnes is a Gram-positive, slow-growing, facultative anaerobe that is found in the skin, the 
sebaceous glands, the oral cavity, the large intestine, the conjunctiva and the external ear 
canal [19]. P. acnes is primarily known as the major cause of inflammatory acne, but is also a 
common pathogen causing deep-seated invasive infections associated with implanted devices, 
such as shoulder prosthesis, neurosurgical shunts, deep brain stimulators and cardiac devices 
[20-22].  
P. acnes is a low-virulent organism, but its ability form biofilm on different biomaterials is 
considered as an important virulence factor for the pathogenesis of infections caused by this 
organism [23]. However, in contrast to staphylococci and enterococci, little is known about 
the molecular mechanism involved in the biofilm biogenesis. A fibronectin-binding protein 
found on the surface of the bacterium was shown to facilitate the attachment to the plasma 
protein film found on many implanted materials [24].  
The relevance of P. acnes in foreign-body infections may be underestimated for several 
reasons. Isolation of this anaerobic organism is difficult and, due to slow growth, up to 14 
days of incubation is recommended for detection [25]. However, whether late growth in an 
enriched growth media reflects infection or only contamination is not always obvious. In 
order to confirm infection, P. acnes should be isolated in a pure culture from multiple 
specimens. Additionally, there is not much data on the spectrum of clinical presentations of P. 
acnes implant-associated infections [23, 25]. Infection typically occurs exogenously during 
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surgery but due to the low virulence of the bacteria, clinical manifestations may be delayed 
for months and even, rarely, for years [20]. A hematogenous route of infection is unusual, but 
was demonstrated in a rabbit model of total joint replacement [26] and in a case-report on a 
prosthetic hip infection (Mihailesku R, Trampuz A, and Borens O, presented at the 30th 
Annual Meeting of The European Bone and Joint Infection Society (EBJIS) in Copenhagen, 
Denmark September, 15-17 2011, poster Nr. 29).   
P. acnes is highly susceptible to several antimicrobials and infections are in general treated 
with penicillins, cephalosporins or clindamycin [27]. Besides the intrinsic resistance to 
metrodinazole, antimicrobial resistance in P. acnes is rare but has been reported for 
antimicrobials used for topical treatment of acne, such as clindamycin and erythromycin [28]. 
For eradication of P. acnes biofilms, penicillin G and linezolid in combination with rifampin 
showed the best activity in vitro [29]. In addition, to the protective effect of the biofilm, it has 
been shown that P. acnes can escape the immune response by resisting phagocytosis and 
surviving inside macrophages [30]. 
Diagnosis and treatment of implant-associated infections. 
 
The diagnosis of implant-associated infections is based on an evaluation of clinical symptoms 
in combination with analysis of microbiological and histopathological samples, and laboratory 
analysis, including leukocyte count in blood and synovial fluid [31]. In recent years, new 
methods and techniques have been proposed, allowing an improved and faster diagnosis, with 
high sensitivity and specificity. The conventional diagnostic method of culturing peri-
prosthetic tissue samples frequently fails in recovering and detecting biofilm bacteria, as the 
biofilm is mainly attached to the implant [31]. Bacterial biofilms can be dislodged from the 
explanted device by sonication, and the resulting sonication fluid can be cultured or analyzed 
by molecular methods. This approach was shown to be more sensitive than peri-prosthetic 
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tissue culture for the microbiologic diagnosis of prosthetic joint infection, especially in 
patients who had received antimicrobial therapy before surgery [32]. New rapid non-culture 
based molecular assays for bacterial identification include multiplex and 16S rDNA 
polymerase chain reaction (PCR) [31, 33] and matrix-assisted laser desorption-ionization 
time-of-flight mass spectrometry (MALDI-TOF MS) [31]. 
Conventional antimicrobial susceptibility tests determine susceptibility of actively replicating 
bacteria, and may thus not be predictive for the treatment outcome in the presence of a 
biofilm. It was shown that an in vitro bactericidal activity against non-growing stationary-
phase bacteria could better predict the treatment outcome in an implant-associated infection 
animal model [34]. Different in vitro methods for evaluation of antimicrobial agents for 
eradication of biofilms have been described. The majority of methods are based on a static 
microplate assay, where biofilms are formed in the wells of a microplate, followed by an 
antimicrobial challenge and quantification of the remaining biofilm by different methods [35-
37]. Microplate assays allow screening of multiple isolates and drugs, and have shown to be 
convenient for fast-growing bacteria forming solid biofilms, such as S. aureus, E. coli and 
Pseudomonas aeruginosa [37]. However, for more slow-growing bacteria, such as P. acnes, 
these assays have not been widely used, which may be due to problems of reproducibility and 
intra-experimental variations, as was shown for the use of crystal violet for staining of P. 
acnes biofilm [38]. Existing methods for antimicrobial susceptibility testing of biofilms are 
too cumbersome and time-consuming for clinical practice, and are currently only suitable for 
research purposes.  
Eradication of an implant-associated infection often includes removal of all foreign-body 
material, and its replacement after several weeks (if needed). This approach requires several 
surgical interventions and causes considerable soft tissue damage and bone stock loss, in the 
case of a prosthetic joint [9]. Therefore, new treatment options using antimicrobials with 
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increased activity against biofilms are being investigated, potentially allowing successful 
eradication of implant-associated infections without removal of the device.  
Antimicrobial therapy. 
 
Due to reduced antimicrobial susceptibility of bacteria in biofilm, a long-term, high-dose 
therapy is required to cure implant associated infections. Table 1 summarizes the 
recommended choice of antimicrobial agent depending on the causative pathogen [9, 11].  
Based on in vitro, animal and clinical data, the optimal antimicrobial therapy has been defined 
for staphylococci and includes the use of rifampin [39]. Another antibiotic that has shown 
good activity against staphylococcal biofilm in vitro and in vivo, and is currently clinically 
evaluated for the treatment of prosthetic joint infections, is the lipopeptide daptomycin [40]. 
Table 1. Antimicrobial treatment of prosthetic joint infections. 
Microorganism Antimicrobial agent 
 First 2-4 weeks Following 8-10 weeks 
Staphylococci rifampin plus  
(flu)cloxacillin 
rifampin plus  
levofloxacin or other 
fluoroquinolone 
Methicillin-resistant staphylococci rifampin plus vancomycin 
or daptomycin 
rifampin plus  
levofloxacin or other 
fluoroquinolone or daptomycin or 
teicoplanin or fusidic acid or 
cotrimoxazole or minocycline 
Streptococci penicillin G or ceftriaxone amoxicillin 
Enterococci 
 
penicillin G or amoxicillin 
or ampicillin or 
daptomycin plus 
aminoglycoside 
amoxicillin 
Penicillin-resistant enterococci 
 
 
vancomycin or daptomycin 
plus aminoglycoside 
 
Gram-negatives ciprofloxacin, 
cefepime or ceftazidime 
plus aminoglycoside 
(nonfermenters) 
ciprofloxacin 
Anaerobes clindamycin clindamycin 
Polymicrobial amoxicillin/clavulanic acid 
or piperacillin/tazobactam 
or imipenem or 
meropenem 
individual regimen 
Adapted from [9, 11].  
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Rifampin. 
  
Rifampin is a semisynthetic derivate of rifamycin, approved for treatment of tuberculosis but 
also widely used in combination therapy for different staphylococcal infections, including 
prosthetic and native valve endocarditis, chronic osteomyelitis and prosthetic joint infections 
[41]. Rifampin acts by binding to the β-subunit of the bacterial DNA-dependent RNA 
polymerase inhibiting the transcription initiation, which confers its bactericidal action [42]. 
The potent activity of rifampin against mycobacteria is due to the ability of the drug to enter 
the host cells, and high concentrations of rifampin has been detected in macrophages, 
endothelial cells and neutrophils [41]. Rifampin also penetrates well into biofilms, which is 
the most important mechanism, supported by strong clinical data, for using the antimicrobial 
in the treatment of biofilm infections. Other hypotheses behind the anti-biofilm activity of 
rifampin, based on in vitro and in vivo data, includes a reduced bacterial adherence to the 
foreign material, an improved activity of other antimicrobials when used in combination, and 
activity against stationary-phase bacteria present in the biofilm [41]. 
Rifampin is always administered in combination with another active antimicrobial to prevent 
a rapid emergence of resistance, which has been described in a wide range of species, 
including S. aureus [43], E. coli [44], Streptococcus pneumoniae [45] and Mycobacterium 
tuberculosis [46]. Resistance is in general due to alterations in the rpoB gene, encoding the β-
subunit of the RNA polymerase. Rifampin resistance can emerge through point mutations, 
insertions or deletions in the conserved regions cluster I-III or near the N-terminal of the rpoB 
[47]. In the majority of cases resistance is due to point mutations. Other more rare 
mechanisms of resistance include duplication of the target, RNA polymerase binding proteins 
and modification of rifampin or its permeability into the cell [47]. 
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Daptomycin. 
 
Daptomycin is a cyclic lipopeptide with rapid bactericidal activity against Gram-positive 
bacteria, including multi-resistant organisms [48]. The mechanism of action, illustrated in 
figure 4, involves a calcium-dependent insertion of the lipophilic tail of the molecule into the 
bacterial cytoplasmic membrane (1), oligomerization of the molecule (2) leading to 
membrane polarization, potassium efflux and eventually rapid cell death without lysis (3) 
[49].  
 
 
 
 
Daptomycin was discovered in the 1980s but clinical trials were stopped due to muscle 
toxicity, which was observed when the drug was administered twice daily at a dose of 4 
mg/kg. In 2003, daptomycin was approved for the treatment of complicated skin and soft 
tissue Gram-positive infections at a daily dose of 4 mg/kg and in 2006 for treatment of 
bacteremia and right-sided endocarditis caused by S. aureus, at a dose of 6 mg/kg [48]. 
However, clinical trials, retrospective studies and case reports on the use of higher doses (up 
to 12 mg/kg), have reported safety and tolerability, and an improved efficiency for the 
treatment of staphylococcal bone and joint infections, bacteremia and endocarditis [51]. In 
addition, in vitro effects, such as an increased rapidity of the bactericidal activity and 
suppression of the emergence of daptomycin resistance, were reported, in presence of higher 
concentrations of the drug [51]. Daptomycin is suitable for once daily dosing due to its 
Figure 4. Mechanism of action of daptomycin. Insertion of the lipophilic tail in a calcium-dependent 
manner (1); oligomerization of the molecule and formation of a trans-membrane pore (2); membrane 
depolarization, potassium efflux and cell death (3) From [50].  
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concentration-dependent activity, half-life of 8 h and demonstrated post-antibiotic effect up to 
6.6 h [48]. 
Daptomycin resistance is currently rare, but has been described in staphylococci and 
enterococci. Mutations in genes encoding for protein implicated in the phospholipid 
biosynthesis, have been detected in laboratory and clinical S. aureus strains exhibiting a 
decreased susceptibility to daptomycin [52]. These mutations are thought to induce a 
reduction in the net-negative charge of the cell membrane, causing an electropulsion of 
daptomycin [52]. In E. faecalis, three deletions in different genes have been demonstrated to 
play a role in daptomycin resistance in vivo [53]. Two genes encode for enzymes of the 
phospholipid synthesis; cls encoding for cardiolipin synthase and GdpD, encoding for 
glycerophosphoryl diester phosphodiesterase. The third gene encodes a membrane protein, 
LiaF, which is thought to be involved in the stress response to antimicrobials acting on the 
bacterial cell envelope [53]. 
Animal models of implant-associated infections. 
 
The key advantage of studying biofilm infections using animal models is the presence of a 
physiological environment and the immune system of the host. In vivo studies are especially 
important for evaluation of antimicrobial agents, as pharmacokinetic and pharmacodynamic 
factors may influence the interaction between the drug and the microorganism, and the drug 
efficacy [54]. Among the different types of biofilm infections, foreign-body infections are 
convenient to study by inserting an implant, which is consequently infected, locally or 
hematogenously. After a preferred duration of infection, the foreign-body can be explanted 
and the presence of a biofilm can be evaluated by different methods, such as examination by 
confocal scanning microscopy of bacterial cells and the extracellular matrix stained with 
specific dyes, or examination by high-resolution electronic microscopy [54]. When studying 
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the efficiency of an antimicrobial treatment, the foreign-body is aseptically explanted after the 
end of therapy and the presence of biofilm bacteria evaluated by CFU-count of bacteria 
detached from the surface by sonication or scraping, or if possible, culture of the whole 
implant. Currently, the most studied animal models are models of catheter-associated urinary 
tract infection, ventilator-associated pneumonia or infection of different materials implanted 
subcutaneously or intraperitoneally on the animal [54]. 
The tissue-cage infection model. 
 
With the primary goal to study host factors implicated in foreign-body infections, a guinea-
pig model with subcutaneous implants (tissue cages) was developed by Zimmerli et al. [55, 
56]. Interesting findings on the immunological level were a deficiency in phagocytic activity 
of neutrophils present in sterile tissue-cage fluid, an inability in killing of catalase-positive 
bacteria indicating a defective oxygen-dependent killing mechanism, and a low local level of 
the cytokine tumor necrosis factor alpha [57]. 
The model was further adapted for investigation of antimicrobial treatment regimens against 
bacterial biofilm infections, and was later also modified for the use in rats and mice. In 
comparison with other more complex foreign-body infection models, the tissue-cage model 
does not require refined surgical skills [56]. Briefly, for the guinea-pig model, four regularly 
perforated Teflon cylinders (figure 5B), allowing accumulation of inflammatory fluid, 
bacterial inoculation and pharmacokinetic studies, are implanted on the flanks of male albino 
guinea-pigs (figure 5A).  After wound healing, approximately three weeks after implantation, 
cages are infected by injection of a well-defined bacterial inoculum [56]. The minimal 
infective dose needed to achieve a stable infection of the cage in guinea pigs is in the range of 
102-103 CFU for staphylococci. In rat or mouse models, the minimal infective dose is higher 
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and immunosupression may be needed to prevent spontaneous healing of the infection [58, 
59]. 
 
 
 
 
Different treatment regimens for biofilm infections have been evaluated using tissue-cage 
infection models. A limitation when using guinea pigs is their intolerance to β-lactam 
antimicrobials and clindamycin, which both cause lethal diarrhea. Additionally, guinea pigs 
only support short-term therapy up to 4 days. Rats are more suited for studying chronic 
infections and long-term therapy, but the infective dose needs to be increased to avoid 
spontaneous healing [56, 59]. When using a novel antimicrobial, a pharmacokinetic profile 
can be established by aspirating of tissue-cage fluid after intraperitoneal injection of different 
doses of the drug. Most antimicrobials are administered twice daily using doses that will 
achieve drug levels in the tissue-cage fluid, equal to the levels obtained in human serum. For 
evaluation of the treatment efficacy the tissue-cages are explanted after the end of therapy and 
the cure rate is determined by dividing the number of culture-negative cages by the total 
number of cages in the treatment group. Additionally, the antimicrobial activity against 
planktonic bacteria present in the fluid within the cage can be evaluated by aspirating cage 
fluid before, during and after treatment (figure 5C) [56].  
  
Figure 5. Guinea-pig foreign-body 
infection model.                                 
A. Subcutaneous insertion of cages.  
B. Tissue-cages (Teflon cylinders).   
C. Aspiration of tissue-cage fluid. 
A 
B 
C 
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Chapter 2.  Aim of the study. 
 
The general aim of the study was investigate novel antimicrobial combinations for the 
eradication of biofilms of difficult-to-treat microorganisms in vitro and in a foreign-body 
infection model using guinea pigs. 
The aim of the first part (chapter 3) was to investigate the activity of daptomycin and 
vancomycin, alone and in combination with gentamicin, against planktonic and adherent E. 
faecalis in vitro and in vivo. 
The aim of the second part (chapter 4) was to investigate the activity of rifampin alone and in 
combination with other antimicrobials against P. acnes biofilm in vitro and in vivo.  
Finally, in the last part (chapter 5) we investigated the in vitro emergence of rifampin 
resistance in P. acnes, and characterized the molecular background in resistant isolates. 
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Chapter 6. General conclusions and outlook. 
 
Implants are increasingly used in modern medicine to improve the quality of life of a 
continuously ageing population. Infections of implants rarely occur but the treatment is 
challenging, and includes intensive antimicrobial therapy for eradication of the biofilm 
growing on the implant surface. Staphylococci cause majority of infections and antimicrobial 
treatment concepts have been optimized with the help of animal and clinical studies. 
However, less prevalent organisms, such as enterococci and fungi, are currently considered as 
difficult to treat, and the optimal treatment is to be defined. Additionally, thanks to improved 
diagnostic tools, microorganisms previously difficult to detect, such as P. acnes, are more 
frequently confirmed as the cause of infection, for which the optimal antimicrobial therapy 
neither not yet has been determined. 
Conventional susceptibility tests may be misleading for guiding the treatment of biofilm 
infections, as they are using metabolically active bacteria for determination of antimicrobial 
susceptibility. In chapter 3, we applied a previously described method using bacteria in 
stationary growth phase, for determination of antimicrobial susceptibility of non-dividing, 
metabolically inactive E. faecalis. We demonstrated an excellent in vitro activity of 
gentamicin against stationary-phase E. faecalis, with an MBCstat of 4 μg/ml. The addition of 
gentamicin at subinhibitory concentrations improved the in vitro activity of vancomycin and 
daptomycin against E. faecalis, both in stationary and logarithmic growth phase.  In chapter 4, 
we established an in vitro assay for the assessment of anti-biofilm activity of different 
antimicrobial agents by microcalorimetry. The assay allowed an indirect quantification of 
biofilm on porous glass beads, based on the growth-related heat produced by the dispersing 
biofilm bacteria. We demonstrated a superior activity of rifampin for eradication of P. acnes 
biofilm (MBEC 16 μg/ml) in comparison with other antimicrobials tested, as was previously 
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shown for staphylococci. The MBECs of penicillin G, daptomycin and ceftriaxone were 
between 32 and 64 μg/ml, whereas clindamycin, levofloxacin and vancomycin only showed 
limited activity against P. acnes biofilms in vitro.   
Based on in vitro results, we investigated the different treatment regimens in a guinea-pig 
model for foreign-body infections. Before initiating treatment studies, the experimental 
conditions were optimized for two organisms of interest. A low infective dose and a short 
duration (3 h) of infection were used for E. faecalis, as treatment failure occurred with all 
treatment regimens when the duration of infection exceeded 24 h. This observation highlights 
the difficulty in treating enterococcal infections and the ability of these bacteria to rapidly 
form persistent biofilms. In contrast to other bacteria, a high infective dose for P. acnes was 
needed to induce a persistent infection without spontaneous decrease in planktonic bacteria in 
cage fluid, possibly due to the effect of immune system and a switch from the planktonic into 
a biofilm growth mode. Despite culture-negative tissue-cage fluid, bacteria were present in 
biofilm on the explanted tissue-cages. This finding was in agreement with the fact that P. 
acnes is often undetectable by culture of cerebrospinal or synovial fluid, despite infection.  
We were able to confirm our in vitro findings in vivo by performing treatment studies. 
Gentamicin alone showed good activity against in vivo biofilm of E. faecalis (cure rate 50 %) 
and improved the cure rate of vancomycin and daptomycin, from 17 % to 33%, and from 25% 
to 55%, respectively. However, the overall cure rates were low, in particular when 
considering the short duration of infection. Despite using a penicillin-susceptible strain, we 
were unfortunately not able to compare our results with regimens containing β-lactams, such 
as penicillin G, ampicillin and amoxicillin, due to restricted antimicrobial tolerance of the 
guinea pigs. The daptomycin combination was the most active antimicrobial regimen and 
could be a potential treatment option for biofilm infections caused by penicillin-resistant and 
vancomycin-resistant enterococci, since there is no daptomycin cross-resistance observed 
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with glycopeptides or β-lactams. Considering the reported emergence of daptomycin 
resistance in enterococci, it should be preferably given at high-dose (8-12 mg/kg in humans) 
and in combination with an aminoglycoside. The dose of 40 mg/kg used in our study 
corresponds to a dose of 8 mg/kg in humans.  
Moreover, we were able to prove the anti-biofilm activity of rifampin against P. acnes in vivo 
(cure rate 36%), and also in this study, a combination with daptomycin showed the highest 
cure rate (63%). As predicted based on in vitro studies, vancomycin and levofloxacin showed 
lower cure rates, both alone (17% and 0%) and in combination with rifampin (46% and 25%). 
We were not able to test penicillin G and ceftriaxone in the animal model, but based on their 
in vitro anti-biofilm activity, these antimicrobials could present potential treatment options in 
combination with rifampin. A rapid emergence of rifampin resistance has been observed in 
several bacterial species, especially if the antimicrobial is administered as monotherapy. In 
our animal studies, rifampin resistant P. acnes isolates were not detected, or proven as the 
cause for treatment failure. If prolonging the duration of treatment, resistance could 
potentially have emerged in the slow-growing P. acnes, but due to limited antimicrobial 
tolerance of the guinea pigs, we were only able to perform a short-term therapy. For long-term 
therapy, a tissue-cage rat model could be used. However, whether a stable P. acnes infection 
could be established in this animal is not certain, as a high infection inoculum already was 
required in the guinea pigs.  Nevertheless, in chapter 5, we demonstrated that in vitro rifampin 
resistance can emerge in P. acnes during progressive exposure to the drug, or spontaneously if 
the bacterial concentration is high with a mutation frequency of 10-9. Mutations in the coding 
region for the rifampin target, rpoB, were associated with an increase in MIC, as previously 
described in other bacterial species. In total five different mutations were found, in cluster I 
and II of the rpoB gene. Interestingly, none of the mutations detected in cluster II conferred to 
high-level resistance, whereas of the mutations found in cluster I, two mutations were 
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associated with high-level resistance and one with low-level resistance. By combination with 
clindamycin, penicillin G or levofloxacin, an emergence of high-level resistance could be 
prevented in vitro. The impact of rifampin resistance in a clinical practice is currently clear, 
but could be predicted by animal studies using our already established model.  
In view of the growing number of implant-associated infections, in combination with an 
increasing prevalence of antimicrobial resistance, new alternative treatment strategies for 
biofilm infections are needed. One approach is to prevent the bacterial attachment to the 
surface by rendering the implant surface antimicrobial but without influencing the host 
biocompatibility. Promising preventive strategies include antimicrobial coating of the device, 
and the use of surface coatings favoring the adhesion of host cells while preventing the 
adhesion of bacterial cells. Another approach, already widely used, is the addition of 
antimicrobial substances within cement used for fixation of prosthetic joints. However, there 
are still unsolved problems regarding the release kinetics of the antimicrobials in vivo, in 
particular the impact of the local and systemic presence of sub-inhibitory drug concentrations 
for the emergence of antimicrobial resistance. When a mature biofilm already is established, 
interference with the cell-to-cell communication by quorum-sensing inhibitors, or degradation 
of the extracellular matrix by biofilm-dispersing enzymes, may improve the eradication of the 
infection.  
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PART II. 
Antifungal susceptibility of molds by isothermal 
microcalorimetry. 
 
 
 
 
56 
 
Chapter 7. General introduction. 
 
Invasive mold infections. 
 
The innate immune system protects effectively against pathogenic fungi and infections are in 
general mild and non-invasive. However, when mold spores are present in large quantities, 
they constitute a health risk, causing allergic reactions and respiratory problems [1] In 
contrast, immunocompromised patients are at high risk for life-threatening infection caused 
by growth of opportunistic molds. The usual patients are neutropenic cancer patients, solid 
organ or hematopoetic stem cell transplant recipients, and patients receiving 
immunosuppressive therapy [2]. Invasive fungal infections are increasingly reported in these 
patient groups, and are associated with high morbidity and mortality rates often above 50 %, 
depending on disease and pathogen [3]. Invasive mold infections occur when fungal conidia 
(figure 1) are inhaled and, in the absence of an immune response, invade the pulmonary tissue 
or sinus through infiltration of hyphae (figure 1), causing an often aggressive disease course. 
Through dissemination of fungal conidia from the initial infection site or through hyphal 
invasion, the mold can spread via blood vessels, eventually causing hemorrhage, necrotic skin 
lesions and brain abscess [2].  
 
 
 
 
 
 
 
Figure 1. Asexual life cycle of Aspergillus 
spp. including conidia formation, 
germination, hyphal formation and branching, 
and formation of a conidiophore.              
From: edscience.net  
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Microbiology. 
 
While Candida and Aspergillus species are the predominant pathogens accounting for  
approximately 80% and 15% of infections, respectively [4], the incidence of non-Aspergillus 
molds is continuously rising [5, 6]. The changing epidemiology may reflect the increased use 
of antifungals for prophylaxis and the introduction of new antifungal agents in clinical use [7]. 
In addition, progress in the field of fungal species identification by the use of molecular tools 
and nucleic-acid sequencing, has allowed identification of species belonging to the same class 
or genus, but exhibiting distinctive susceptibility patterns [8, 9]. 
A. fumigatus is the most prevalent species, isolated in up to 90% of patients with invasive 
aspergillosis[10], followed by A. flavus and A. niger [11]. Nevertheless, increased prevalence 
of rare Aspergilli exhibiting antifungal resistance, such as A. terreus and A. lentulus [12] 
challenges the already difficult treatment. Infections due to non-Aspergillus molds, such as 
species from the Mucorales order, Fusarium spp. and Scedosporium spp., are particularly 
difficult to treat, because of rapid tissue invasion and their intrinsic resistance to most first-
line antifungal agents [13, 14]. The most prevalent species in the order of Mucorales include 
Rhizopus arrhizus, Rhizomucor pusillus and Lichtheimia corymbifera [15], whereas F. solani 
is the principal pathogen among Fusarium species [16]. The genus Scedosporium includes at 
least two medically important members Pseudallescheria apiosperma and S. prolificans [17], 
which may colonize the respiratory tract and disseminate locally or systemically. S. 
prolificans, in particular, is highly resistant to most antifungal agents [9].  
Diagnosis. 
 
Due to the high mortality associated with invasive mold infections, a rapid diagnosis is crucial 
for the treatment outcome and an immediate start of appropriate antifungal therapy[18]. 
Conventional diagnostic methods include tissue culture and histology, bronchoalveolar lavage 
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(BAL), chest X-ray and computed tomography scan. These methods are invasive, not 
sufficiently sensitive or specific, and results are often not available in time to be clinically 
useful [18]. During the past decades, newer less invasive and non-culture-based diagnostic 
assays, such as the galactomannan test and the 1,3-β-D-glucan assay, have been developed. 
Galactomannan is a polysaccharide component, specific to the cell wall Aspergillus spp., 
which is released in the serum during hyphal formation and growth [11]. 1,3-β-D-glucan is 
another component of the fungal cell wall present in a wide range of species, except the 
Mucorales, and can thus be used as a panfungal marker [11]. Molecular-based diagnostics can 
detect fungi with high sensitivity providing results rapidly. Nucleic-acid based diagnostic 
techniques, such as polymerase chain reaction (PCR), represent the currently fastest growing 
diagnostic segment, but are not yet commercial due to lack of standardization [18]. 
Antifungals. 
  
The three major classes of antifungals currently used for treatment of invasive mold 
infections, summarized in figure 2 [19], owe their antifungal activities to a direct interaction 
with, or synthesis inhibition of, ergosterol (amphotericin B and triazoles) or 1,3-β-D-glucan 
(echinocandins). Ergosterol is the main component of the fungal cell membranes, equivalent 
to cholesterol in mammalian cells. 1,3-β-D-glucan, on the other hand, composes together with 
α-glucan, mannan and chitin the fungal cell wall [20]. 
 
 
 
 
 
Figure 2. Overview of the mechanisms 
of action of the three major antifungal 
classes, amphotericin B, the azoles, 
including the triazoles, and the 
echinocandins, used for treatment of 
invasive mold infections. From (52). 
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Amphotericin B. 
 
The polyene amphotericin B was for a long time considered as the “gold standard” for 
antifungal therapy. The compound was originally extracted from Streptomyces nodosus and 
was used as an antifungal agent already in 1959 [21]. The polyenes act by binding to 
ergosterol in the fungal cell membrane, leading to formation of membrane-spanning channels 
that cause leakage of cellular components and osmotic cellular lysis, and eventual cell death 
[20]. The second mechanism of action known, primarly for killing of Candida spp., involves 
oxidative damage of the cell [20].  
The antifungal spectrum of amphotericin B is particularly broad and several fungal species are 
susceptible to low concentrations of the drug. Amphotericin B is commonly used in patients 
with suspected invasive fungal disease, but without documentation of Aspergillus as the 
causative agent [10], and as the first choice for treatment of mucormycosis [22]. Due to the 
toxicity of conventional amphotericin B [11], lipid formulations, including liposomal 
amphotericin B, amphotericin B lipid complex and amphotericin B colloid dispersion, were 
developed in the late 1990s [21]. Several studies have demonstrated that the lipid 
formulations of amphotericin B are consistently less toxic and may be even more effective 
than the conventional drug [21]. 
Triazoles. 
 
The triazoles are the largest class of antifungal compounds and include fluconazole, 
itraconazole, voriconazole and posaconazole, as well as isavuconazole which is still in 
development. All compounds, except fluconazole, show activity against molds and are 
relatively well tolerated [23]. Voriconazole is a synthetic azole derivative of fluconazole, 
which has been shown to be superior to amphotericin B for the primary treatment of invasive 
aspergillosis [24], and is additionally active against Fusarium and Scedosporium spp. [14]. 
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 Posaconazole is the most recent azole in clinical use with a wide antifungal spectrum, also 
showing activity against Mucorales spp. [23]. Posaconazole is primarly used for salvage 
therapy in patients with invasive aspergillosis, and as prophylaxis for neutropenic patients or 
hematopoietic stem cell transplant recipients [23]. The oral bioavailability of posaconzole is 
highly variable and therapeutic drug monitoring is recommended [25]. 
The triazoles inhibit the synthesis of ergosterol from lanosterol, targeting the the cytochrome 
P450 dependent 14-α-demethylase (CYP51), which catalyses the reaction [23]. Consequently, 
it leads to the substitution of methylated sterols and ergosterol depletion in the fungal 
membrane, as well as accumulation of toxic sterol intermediates finally causing inhibition of 
fungal growth [19]. Triazoles are in general fungistatic, with the exception of voriconazole 
and itraconazole exhibiting fungicidal activity against Aspergillus spp. [23]. 
Azole resistance. 
  
Besides intrinsic antifungal resistance, acquired resistance in molds is rare. Nevertheless, 
clinical and laboratory studies have revealed that A. fumigatus can develop azole resistance, 
generally due to mutations in the cyp51A gene, encoding the target CYP51[19]. In A. 
fumigatus, different substitutions at codons 54, 98, 138, 220 and 448, and a 34-bp tandem 
repeat in the promoter region, are associated to resistance to one or more azoles [19]. Azole 
resistance can develop during azole therapy and clinical data suggests that reduced in vitro 
susceptibility is associated with increased probability of failure to azole therapy [19]. 
Additionally, a possible fungicide-driven route of resistance has been described proving a link 
between the use of azole fungicides in the environment and resistance development to medical 
azoles [26]. 
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Echinocandins. 
 
The newest class of antifungal agents is the echinocandins, including caspofungin, 
anidulafungin and micafungin. The echinocandins are large lipopeptides that act by inhibiting 
the fungal 1,3-β-D-glucan synthase, responsible for the biosynthesis of 1,3-β-D-glucan. The 
precise interaction between the drug and its target enzyme on a molecular level is not yet 
elucidated [27]. The echinocandins show concentration-dependent fungicidal activity against 
Candida spp. but only fungistatic activity against Aspergillus spp., where they introduce 
abnormal hyphal morphology (figure 3), lysis of rapidly growing bud tips and a reduced 
growth rate.  
 
 
 
 
Echinocandins are not recommended as initial treatment of aspergillosis, due to their 
fungistatic activity but can be used in combination with amphotericin B and voriconazole 
[28]. Against other non-Aspergillus molds echinocandins show limited or no activity [29]. 
Antifungal combinations. 
 
The availability of new antifungal agents, with novel modes of action, has raised the interest 
for combination therapy, when investigating new treatment options. Synergistic drug 
interactions could increase antifungal efficacy, prevent the emergence of resistance, and 
provide broader-spectrum antifungal activity than monotherapy regimens [30]. On the other 
hand, in case of antagonistic interactions, combination therapy may decrease the antifungal 
efficacy and increase toxicity [30]. In addition, if two or more antifungals are administered 
Figure 3. Abnormal hyphal growth of 
A. fumigatus, characterized by short 
abundant branching, in the presence of 
anidulafungin at a concentration of 
0.03 μg/ml. Magnification x 40. 
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simultaneously, the cost of the therapy will be greater and the risk for drug interactions 
increases [31]. Several antifungal combinations appear to have an improved activity in vitro 
and in animal models, but no appropriate clinical trials have so far been conducted [31]. 
Based on in vitro assays, potential antifungal combinations against Aspergillus spp include 
amphotericin B plus caspofungin or voriconazole, and voriconazole plus caspofungin, 
micafungin or  itraconazole [31]. 
Antifungal susceptibility testing. 
 
Different methods, including broth- and agar-based assays, exist for determination of in vitro 
antifungal susceptibility of molds. Both the Clinical Laboratory Standards Institute (CLSI) 
[32] and the Antifungal Susceptibility Testing Subcommittee of EUCAST (EUCAST-AFST) 
[33] guidelines recommend a microbroth dilution assay for the determination of the minimal 
inhibitory concentration (MIC). The guidelines recommend RPMI 1640 (CLSI) or RPMI 
1640 supplemented with 2% glucose (EUCAST) as test culture media. Moreover, CLSI 
recommend an inoculum of 0.4 - 5 x 104 conidia/ml adjusted by spectrophotometry, whereas 
EUCAST use an inoculum of 1 - 2.5 x 105conidia/ml determined by counting using a 
hemocytometer chamber. Both tests are interpreted by visual examination at 24 h for 
Mucorales species and at 48 h for other species and the MIC is defined as the lowest 
concentration causing 100% of growth inhibition. 
Due to the different mechanism of action of the echinocandins, the minimal effective 
concentration (MEC) was introduced to evaluate the antifungal activity, and is proposed as 
endpoint by both guidelines. The MEC is defined as the lowest concentration of drug causing 
abnormal growth, characterized by short abundant branching as observed by microscopy 
(figure 3) [34]. CLSI and EUCAST define the MEC as the lowest concentration resulting in 
macroscopic small compact rounded hyphal forms or microcolonies. Determination of the 
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MEC represents a subjective assessment of the appearance of growth, requiring experienced 
personnel for accurate interpretation. 
Microbroth dilution assays are labor-intensive and need experienced personnel for 
interpretation. Therefore, several commercial test assays have been developed to facilitate the 
antifungal susceptibility testing. Sensititre Yeast One is a colorimetric microdilution method 
based on the CLSI guidelines for susceptibility testing of yeast [35]. The assay includes 
Alamar-blue that converts into pink in the presence of growth, which facilitates the test 
interpretation. Sensititre Yeast One showed good correlation with standard susceptibility 
testing of molds for amphotericin B and triazoles, whereas further evaluation is needed for 
echinocandins [36-38]. Agar-based methods, including disk diffusion testing and Etest , are 
easy-to-perform and cost efficient. Currently, there are no standardized conditions for the use 
of disk diffusion testing of molds but test parameters have been evaluated for different mold 
species, including optimization of culture conditions and correlation of the inhibition zone 
with MIC and MEC values obtained by the conventional method [39]. However, the disk 
diffusion method does not allow differentiation between susceptible, intermediate and 
resistant values for all species and antifungals [39]. Etest has shown good correlation with the 
microbroth dilution method for testing amphotericin B and triazoles against molds, but its 
utility for testing echinocandins is not fully evaluated [40, 41].  
Susceptibility assays for evaluating antifungal combinations. 
Microdilution broth checkerboard is the most commonly technique used to study antifungal 
combinations in vitro. The interaction is assessed based on the fractional inhibitory 
concentration (FIC) index [42]. The FIC is determined for each drug by dividing the MIC of 
the drug in combination by the MIC of the drug alone. A FIC index of < 0.5 indicates synergy 
and an index above 4 indicates antagonism. Majority of in vitro combination studies report 
results with FIC indices within the range of 0.5 to 4 concluding indifference or additivity [31]. 
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The validity of this FIC range has been questioned, as it was chosen without in vivo or clinical 
correlation studies [43]. There are only few studies that have been using other methods, such 
as time-kill studies, for assessing antifungal combinations against molds. However, the utility 
of conidia in time-kill studies is not clear as conidia generally are absent in infected tissues 
and the fungicidal activity against actively growing hyphae would be more predictable for the 
treatment outcome [44, 45].  
Clinical relevance of antifungal susceptibility testing . 
 
Due to the often complex status of the host, it is difficult to confirm a correlation between in 
vitro susceptibility and treatment outcome, and establishing clinical breakpoints for molds is 
challenging. In addition, in vitro tests do not consider the dynamic biology of the molds in 
vivo, such as hyphal formation and infiltration, the pharmacokinetics at the site of infection 
and the host immune response [46]. Most often a poor outcome is related to the status of the 
host, a late diagnosis or a lack of appropriate antifungal therapy. The disagreement between in 
vitro and in vivo data is described by the “90-60 rule”, according to which infections caused 
by susceptible strains respond to treatment in 90% of the cases, whereas in the case of 
resistant strains, the treatment response is 60 % [47].  
The two standard methods for antifungal susceptibility testing (CLSI and EUCAST) differ in 
inoculum size and culture media, which influence the MIC and MEC values obtained. 
Breakpoints suggested by the CLSI can thus not be extrapolated to the EUCAST method and 
vice versa [48]. In addition, invasive mold isolates are often not identified at species level, 
despite that variability in susceptibility within genus has been reported [9, 12]. Nevertheless, 
the antifungal susceptibility subcommittee of EUCAST recently published breakpoints for 
amphotericin B, itraconazole and posaconazole for Aspergillus spp. based on epidemiological 
cut-off MIC values and clinical experience, but without a direct correlation between MIC and 
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clinical outcome [25]. For posaconazole, pharmacokinetic and pharmacodynamic data were 
also included. For A. fumigatus breakpoints of ≤ 1 μg/ml and > 2 μg/ml, corresponding to 
susceptible and resistant, respectively, were determined for amphotericin B and itraconazole. 
MIC values of ≤ 0.12 μg/ml and > 0.25 μg/ml, were the breakpoints for posaconazole. There 
are currently not sufficient data for assigning breakpoints for other Aspergillus spp.. Besides 
for optimization of antifungal therapy, performance of antifungal susceptibility testing is 
highly important for a continued surveillance of resistance as the current number of antifungal 
agents is limited. 
Use of isothermal microcalorimetry in microbiology. 
  
Microcalorimetry is a highly sensitive method, which enables measurement of microbial heat 
production in the range of microwatt. Replicating microbes produce heat proportionally to 
their metabolism and growth rate [49] . By isothermal microcalorimetry, variations in heat are 
measured under constant temperature and pressure [50]. A bacterial or fungal culture 
constitutes a close thermodynamic system, which will exchange heat with its surrounding 
proportionally to the number of replicating organisms. The heat produced can be recorded in 
real time, and plotted as heat flow (Watt) versus time (figure 4). The slope of the heat flow 
curve at each time point depends on the replication rate, whereas the total heat (Joule) (the 
area under the heat flow curve) is proportional to the final number of cells (figure 4) [49]. 
Currently, most of the isothermal microcalorimeters used for microbiological measurements 
are multi-channel batch calorimeters of heat-conduction type, such as “The Thermal Activity 
Monitor” (TAM 48, TA Instruments, New Castle, DE, USA), shown in figure 5A [50]. 
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Figure 5.  
A.The isothermal micrcocalorimeter TAM 
48 (TA Instruments) with 48 independent 
channels.  
B A schematic picture of a calorimetric 
channel including the heat sink, functioning 
like an inert reference and the sample 
(hermetically closed, 4 ml glass ampoule). 
The thermopile measures the difference in 
heat between the sample and the reference 
under a constant temperature. 
From: TA Instruments (personal 
communication). 
 
 
 
Figure 4. Relation between the microcalorimetric measurements and their biological equivalents. 
The heat flow represents the activity (growth rate) of a microbial culture. The area under the heat-flow 
curve gives the total amount of heat produced, representing the products resulting from microbial activity 
(total number of cells, biomass). Adapted from [49]. 
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Heat-conduction calorimeters continuously measure difference in temperature between the 
sample and the heat sink (figure 5B). The heat sink functions like a thermally inert reference, 
and is generally made of aluminium [49]. The heat between the sample and the heat sink is 
transferred through a thermopile, which allows monitoring of consumed or produced heat by 
converting minor temperature differences into electrical signals [51]. The sensitivity of the 
TAM 48 is 0.2μW, which corresponds to approximately 100 000 bacteria assuming that a 
bacterial cell produces ~2pW [49]. The reaction vessel, including the sample and the heat 
sink, is positioned in a liquid (water or oil) thermostat, ensuring a temperature stability of 10-
5°C [50]. The temperature of the thermostat is adjustable in the range of 15-150 °C, and is in a 
microbiological setting normally set at 37°C.  
 
An advantage of microcalorimetry for a microbiological assay, besides the sensitive growth 
detection, is that samples do not require specific preparation and they can still be used for 
further analysis after the microcalorimetric measurement. On the other hand, a major 
drawback is the measurement of non-specific signals, related to all chemical and physical 
reactions taking place in the sample [49]. Moreover, to perform an isothermal measurement a 
closed system is required, thus the sample is placed in a hermetically sealed ampoule (figure 
5B). Chemical factors, such as oxygen depletion and accumulation of metabolic waste 
products, might influence the microbial growth and need to be taken into account [51]. 
Potential applications of isothermal microcalorimetry in clinical microbiology include 
primarily early growth detection and determination of antimicrobial susceptibility. A 
microcalorimeter measures all the growth-related heat originating from the sample and 
identification down to species level may be difficult, particularly in the case of mixed 
cultures. However, the use of selective growth media could allow the recovery and detection 
of specific microbes. During the last years, there have been several reports on the utility of 
isothermal microcalorimetry for growth detection of different pathogens, including urinary 
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tract pathogens [52] and mycobacteria [53], and detection of bacterial growth in donated 
blood platelets [54] and in cerebrospinal fluid from a rat model of bacterial meningitis [55]. 
Determination of antimicrobial susceptibility can be performed by incubation of the isolated 
pathogen with the antimicrobial of interest. Growth of susceptible microorganisms is inhibited 
and heat will not be produced, whereas resistant microbes are not inhibited and heat is 
produced also in the presence of the antimicrobial agent. The use of isothermal 
microcalorimetry for this application was reported for a rapid (5 h) differentiation between 
methicillin-susceptible and methicillin-resistant S. aureus [56], and determination of 
antimicrobial susceptibility of Escherichia coli , S. aureus [57], mycobacteria [58] and 
Borrelia burgdorferi (Achermann Y, Steinhuber A, Seiler E, Vogt M, and Trampuz A, 
presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy 
(ICAAC) in Washington, DC, 12-15 September 2009, poster Nr. 198). Isothermal 
microcalorimetry was also shown to be a promising tool for evalutation of anti-parastic drugs 
against Schistosoma mansoni [59], Trypanosoma brucei and Plasmodium falciparum [60] . 
In order to render the currently available microcalorimeters suitable for routine microbiologic 
procedures, an input from the technical side is needed to make the instrument more user-
friendly and enable automated high-throughput screening. In addition, the current cost of 
multichannel calorimeters is too high for a cost efficient clinical laboratory, taking into 
account the hands-on time and consumables. However, for experimental microbiology, an 
isothermal multichannel microcalorimeter is a valuable tool for evaluation of antimicrobial 
inhibitory profiles, including dose and time dependency and evaluation of drug-drug 
interactions.
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Chapter 8.  Aim of the study. 
 
The general aim of the study was to investigate the growth-related heat production of 
medically important molds and the effect of antifungal agents on the heat production by 
isothermal microcalorimetry. The microcalorimetric results were compared with conventional 
methods for susceptibility testing. 
The first specific aim (chapter 9) was to evaluate microcalorimetry for antifungal 
susceptibility testing of Aspergillus species, including non-fumigatus species.   
The second specific aim (chapter 10) was to validate the first study by testing other molds, 
such as species from the Mucorales order, Fusarium and Scedosporium species. 
Finally (chapter 11), we used microcalorimetry for evalutation of antifungal combinations 
against A. fumigatus and A. terreus. 
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Supporting information 
 
Figure S1. Heat flow (left panel) and total heat (right panel) of Aspergillus terreus in the presence of 
amphotericin B (A), voriconazole (B) and anidulafungin (C) in SDB medium using an inoculum of 
~104 conidia/ml. Numbers indicate the antifungal concentration (in mg/L); GC denotes growth control 
without antifungals.
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 Figure S2. Heat flow (left panel) and total heat (right panel) of Aspergillus flavus in the 
presence of amphotericin B (A), voriconazole (B) and caspofungin (C). For details see legend 
to Figure S1. 
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Figure S3. Heat flow(left panel) and total heat (right panel) of Aspergillus niger in the 
presence of amphotericin B (A) posaconazole (B) and caspofungin (C). For details see legend 
to Figure S1.  
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Figure S4. Heat flow (left panel) and total heat (right panel) of Aspergillus oryzae in the 
presence of amphotericin B (A) posaconazole (B) and anidulafungin (C). For details see 
legend to Figure S1.  
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Figure S5. Heat flow (left panel) and total heat (right panel) of Aspergillus lentulus in the 
presence of amphotericin B (A) voriconazole (B) and anidulafungin (C). For details see 
legend to Figure S1.  
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Figure S6. Heat flow (left panel) and total heat (right panel) of Aspergillus nidulans in the 
presence of amphotericin B (A) posaconazole (B) caspofungin(C). For details see legend to 
Figure S1.  
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Figure S7. Heat flow (left panel) and total heat (right panel) of Aspergillus fumigatus CM-237 (wild 
type) MIC 0.06 (A), CM-796 (∆cyp51a/b) MIC 16 (B) and CM-2097 (∆cyp51a) MIC 16 (C) in the 
presence of posaconazole. For details see legend to Figure S1.  
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Table S1. Calorimetric characteristics of Aspergillus species in SDB at 37°C. The inoculum was ~104 conidia/ml. 
Species TTD (h) Peak (µw) TTP (h) TH 24h (J) TH 48h (J) TH 72h (J) 
A. fumigatus ATCC 204305 4.5 (3.0-5.8) 250 (203-277) 16.4 (11.0-18.6) 4.5 (4.3-4.8) 4.7 (4.3-5.1) 4.8 (4.4-5.2) 
A. fumigatus CM-237 3.6 (3.3-3.9) 219 (212-220) 14.5 (14.5-18) 4.5 (4.4-4.7) 4.6 (4.5-4.9) 4.7 (4.6-4.9) 
A. fumigatus CM-796 4 (3.7-4.5) 212 (202-232) 19.7 (16-20.9) 4.6 (4.4-4.7) 4.7 (4.5-4.9) 4.7 (4.6-4.8) 
A. fumigatus CM-2097 14 (12.5-15.4) 129 (123-134) 30.5 (27.6-33.4) 1.2 (0.65-1.8) 4.8 (4.7-4.9) 4.9 (4.8-5) 
A. terreus ATCC 10690 5.5 (5-6.7) 143 (139-150) 30.2 (29.7-30.8) 1.4 (1.4-1.7) 5.6 (5.5-6) 5.6 (5.5-6) 
A. flavus ATCC 204304 3.8 (1.7-6.1) 162 (114-164) 25 (15.9-25.5) 5.8 (3.3-5.8) 8.3 (6-8.3) 10 (10-10.1) 
A. lentulus CBS117.885 4.7 (4.3-4.7) 180 (170-190) 22.9 (15-22.9) 4.5 (4.4-4.6) 5 (4.7-5.1) 5.1 (4.7-5.2) 
A. niger Clinical isolate  7.7 (3.7-12.7) 103 (62-129) 23.3 (21-32.5) 2.9 (1.9-4) 4.4 (3.6-4.7) 4.9 (4.8-4.9) 
A. nidulans Clinical isolate  4.4 (4.4-9.6) 176 (165-205) 24.2 (18-24.5) 3.3 (3.1-4.8) 5.2 (5-5.4) 5.5 (5.4-5.6) 
A. oryzae Clinical isolate  4.3 (2.1-6.3) 152 (146-157) 18.4 (13.3-26.8) 5 (3-6.6) 7.9 (6.8-8.7) 8.6 (8.1-9) 
NOTE. Detection time was defined as exponential increase of the heat flow until 5 μW. TTD; time to detection, TTP; time to peak, TH; total heat. 
* Values are median values from the ≥ 3 replicates tested.
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Abstract  
 
Combining two antifungal agents with synergistic activity may improve the treatment 
outcome of invasive mold infections. We evaluated a highly sensitive assay for testing the 
activity of antifungal combinations against Aspergillus fumigatus and A. terreus based on 
their growth-related heat production (microcalorimetry). In parallel, microscopical evaluation 
of antifungal activity was performed by the checkerboard microdilution broth assay. 
Amphotericin B and voriconazole, alone or in combination with caspofungin or 
anidulafungin, at concentrations of 0.125 x, 0.25 x, 0.5 x or 1 x MIC (or the MEC for 
echinocandins), were tested in Sauboraud dextrose broth containing 2.5 x 105 conidia/ml. 
Heat production was measured for 48 h at 37°C. A synergistic effect was defined as an 
increased delay of fungal heat-production in the presence of an antifungal combination 
compared to each drug alone at the same concentration. For A. fumigatus, the addition of 
caspofungin to amphotericin B and voriconazole, delayed the heat production with up to 4.1 
and 7.4 h, respectively, whereas anidulafungin caused a delay up to 11.2 and 11.8 h, 
respectively. For A. terreus, the addition of caspofungin to amphotericin B and voriconazole, 
delayed the heat production with up to > 16.2 and 7.6 h, respectively, whereas anidulafungin 
caused a delay up to 10.9 h and 4.1 h, respectively. Growth reduction and change in hyphal 
morphology, observed by microscopy were in accordance with the microalorimetric data. 
Microcalorimetry enables an accurate and real-time evaluation of antifungal combinations 
against Aspergillus species and merits further evaluation for testing of other mold species and 
antifungal combinations. 
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Introduction. 
 
In the last decades an increased prevalence of invasive mold infections has been reported (14, 
17). The mortality rate associated with invasive infection is high and an early start of efficient 
antifungal treatment regimen is crucial for an improved outcome (11). The availability of new 
antifungal agents with different targets and modes of action has raised the interest for 
investigation of combination therapy to improve the treatment outcome. Drug combinations 
with synergistic activity could potentially increase the antifungal efficacy, prevent the 
emergence of resistance, and provide a broader antifungal spectrum for initial empiric therapy 
(10). However, combination therapy may also decrease the antifungal efficacy in case of 
antagonistic drug-drug interaction, increase the drug toxicity, promote spread of resistance 
and considerably rise the healthcare expenses (10). Therefore, investigation of antifungal 
activity of combination regimens is important and clinically relevant, as it may help planning 
the design of clinical trials aiming to improve treatment outcome of invasive mold infections.  
Only few in vitro assays are currently available for testing of the activity of two or more 
antifungal agents. The checkerboard microdilution broth assay is the most widely used 
method to study antifungal combinations. The drug-drug interaction is assessed based on the 
fractional inhibitory concentration (FIC) index, determined by dividing the MIC of each drug 
in combination by the MIC of the drug alone (19). A FIC index of < 0.5 indicates synergy and 
an index above 4 indicates antagonism. The majority of combination studies report results 
with FIC indices ranging between 0.5 and 4, concluding indifference or additivity (22). 
However, the validity of this FIC range has been questioned, as the correlation with clinical 
outcome is lacking (15). Few studies have investigated other in vitro assays, such as time-kill 
studies. However, the utility of conidia in time-kill studies is not clear as conidia generally are 
absent in infected tissues and the fungicidal activity against actively growing hyphae would 
be more predictable for the treatment outcome (12, 18). 
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We recently demonstrated the use of isothermal microcalorimetry for real-time antifungal 
susceptibility testing of Aspergillus spp. (8) and non-Aspergillus spp. (9). Heat produced by 
replicating microorganism can be measured by isothermal microcalorimetry in the range of 
microwatt with high sensitivity (23). In the presence of an antimicrobial agent, the growth-
related heat production is suppressed, which can be used to assess the susceptibility of an 
organism of interest. It was shown that amphotericin B, triazoles and echinocandins affected 
the heat-flow profiles of Aspergillus spp. in different manners, depending on their ability to 
inhibit or kill molds (i.e. exhibit fungicidal or fungistatic activity). These effects were 
observed particularly with echinocandins when using Sabouraud dextrose broth (SDB), but 
not when using RPMI medium, recommended for routine antifungal susceptibility by CLSI 
(4) and EUCAST (7). 
The aim of this study was to evaluate the effect of adding caspofungin or anidulafungin to 
voriconazole and amphotericin B against A. fumigatus and A. terreus using isothermal 
microcalorimetry. Antifungals were chosen based on the clinical guidelines, which generally 
recommends voriconazole as first choice for the treatment of invasive aspergillosis and lipid 
formulation of amphotericin B is a valuable alternative (21, 24). For therapy in patients not 
responding to single-drug therapy adding an echinocandin, such as caspofungin, micafungin 
or anidulafungin has to be considered (24).  
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Methods. 
 
Test organisms. A. fumigatus ATCC 204305 and A. terreus ATCC 10690 were used. Molds 
were subcultured for 3-5 days prior to testing on Sabouraud dextrose agar (SDA) at 37°C. 
Stocks of each strain were maintained in water at 4°C for short-term storage and in SDB-20% 
glycerol at -80°C for long-term storage. An inoculum of ~5 x 107 spores/ml was prepared in 
sterile 0.9% saline. The exact inoculum size was determined by microscopic enumeration of 
conidia using a hemocytometer (Neubauer chamber; Assistent, Sondheim, Germany).  
Antifungals. Amphotericin B (Sigma, St. Louis, MO, USA), caspofungin (Merck & Co., 
Whitehouse Station, NJ, USA), voriconazole and anidulafungin (Pfizer Pharma AG, Zürich, 
Switzerland) were tested.  
Susceptibility and synergy testing by microbroth dilution. Microdilution broth was 
performed as described in the EUCAST-AFST E.Def. 9.1 document (7) but SDB was used 
instead of RPMI medium with 0.2% glucose. After inoculation (2.5 x 105 spores/ml), 
microdilution plates were incubated at 37°C and read after 24 h and 48 h. MIC values for 
amphotericin B and triazoles were determined visually and by inverted contrast light 
microscopy(Nikon Eclipse TS100, 40X/0.65). as the lowest concentration of drug that caused 
complete inhibition of fungal growth compared to the growth control at 24 h and 48 h. The 
minimum effective concentration values for caspofungin and anidulafungin were determined 
(at 24 h), defined as the lowest drug concentration at which short, stubby, and highly 
branched hyphae were observed (13).  
Antifungal combinations were tested according the checkerboard methodology (19). The drug 
dilutions were prepared at four times the strength of the final concentration following the 
CLSI drug dilution scheme. After 24 h and 48 h of incubation at 37°C plates wells containing 
following concentrations alone or in combination were examined by inverted contrast light 
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microscopy; 0.125 x, 0.25 x, 0.5 x and 1x MIC (or MEC for caspofungin and anidulafungin). 
Experiments were repeated three times. 
Susceptibility and synergy testing by microcalorimetry. An isothermal microcalorimeter 
(TAM III, TA Instruments, Newcastle, DE, USA), equipped with 48 calorimetric channels 
and a detection limit for heat production of 0.2 µW was used. The inoculum was diluted in 
SDB (Oxoid CM0147; Basingstoke, Hampshire, UK) to a concentration of 1.5 x 107 
spores/ml. 0.05 ml of fungal suspension was added to microcalorimetric ampoules containing 
2.95 ml of SDB and 2-fold dilutions of antifungals for a final inoculum of 2.5 x 105 spores/ml. 
For combination studies the two antifungals tested were combined at concentrations of 0.125 
x, 0.25 x, 0.5 x and 1 x MIC (or MEC for caspofungin and anidulafungin). A synergistic 
effect was defined as an increased delay of fungal heat-production in the presence of an 
antifungal combination compared to each drug alone. SDB without antifungals served as 
growth control and SDB alone as negative control. In addition to the growth media, 1 ml air 
was present in the headspace of the ampoule. The ampoules were air-tightly sealed and 
introduced into the microcalorimeter, first in the equilibration position for 15 minutes to reach 
37.0000°C and avoid heat disturbance in the measuring position. Heat flow was recorded up 
to 48 h. The time to reach 20 μW was recorded. Experiments were repeated three times. Data 
analysis was accomplished using the manufacturer’s software (TAM Assistant, TA 
Instruments, New Castle, DE, USA) and exported for further data analyses and graphic 
presentation. Figures were plotted using GraphPad Prism 5.0 (GraphPad Software, La Jolla, 
CA, USA).  
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Results. 
 
Antifungal susceptibility. The MIC and MEC values for A. fumigatus and A. terreus as 
determined by visual examination and microscopy at 24 h and 48 h are summarized in table 1. 
MIC values determined by microscopy were one or two two-fold dilutions higher than MIC 
values read by visual inspection. The MIC read at 48 h and MEC read at 24 h for by 
microscopy was used for microcalorimetric and combination studies. Time to heat detection 
(heat flow above 20 W) of the growth control was 7.0 ± 1.6 h and 12.6 ± 0.4 h for A. 
fumigatus and A. terreus, respectively. Voriconazole (Fig. 1A) and amphotericin B (Fig. 2A) 
delayed heat production in a concentration-dependent manner with a complete inhibition at 
MIC after 48 h of incubation. The highest concentration of amphotericin B tested (16 µg/ml) 
inhibited the heat production of A. terreus for 33.7 ± 3.2 h, causing a delay to heat detection 
of 24.7 ± 4.6 h in comparison with the growth control but did not achieve complete inhibition. 
The growth-related heat produced was in agreement with the growth observed by microscopy 
(Fig. 1A and 2A), whereas visual growth not yet was observed at the same time point. 
Caspofungin and anidulafungin alone did not delay heat production but decreased the peak 
heat-flow (Fig. 1B and 2B), which could be correlated with the change of hyphal morphology 
observed by microscopy. 
Evaluation of antifungal combinations. The effect of the addition of an echinocandin to 
amphotericin B or voriconazole was evaluated by calculating the delay of time to heat 
detection (heat flow above 20 μW) in presence of a combination in comparison to the drug 
alone at 0.125 x, 0.25 x, 0.5 x and 1 x the MIC or MEC. In parallel the same combinations 
(according to checkerboard dilution scheme) were examined by microscopy. 
Microcalorimetric results are summarized in table 2 showing the delay of fungal heat-flow (in 
h) in presence of an antifungal combination compared to growth control, and the difference 
(in h) in heat detection of combinations compared to amphotericin B or voriconazole alone.  
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Table 1. Antifungal susceptibility of A. fumigatus and A. terreus determined by visual examination and microscopy at 24 and 48h. 
 
 
 
  MIC ( g/ml) MEC ( g/ml) 
Strain Time Amphotericin B Voriconazole Caspofungin Anidulafungin 
  Visual Microscopy Visual Microscopy Microscopy Microscopy 
A. fumigatus 
24 h 0.25 1 0.25 0.5 0.125-0.25 0.015-0.03 
48 h 1 2 0.25 0.5 0.25 0.03 
A. terreus 
24 h 2 4 0.25 0.5 0.25-0.5 0.03 
48 h 8 16 0.5 0.5 0.5 0.03 
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Table 2. Delay of fungal heat-flow (in h) in presence of an antifungal combination compared to growth control and the difference (in h) in heat detection of combinations 
compared to amphotericin B or voriconazole alone. Experiments were performed three times and values are represents mean and standard deviation. 
 0.125 x MIC/MEC 0.25 x MIC/MEC 0.5 x MIC/MEC 1 x MIC/MEC 
 TTD (h) Delay (h) TTD (h) Delay (h) TTD (h) Delay (h) TTD (h) Delay (h) 
A. fumigatus         
AMB + CAS 10.3 ± 1.1 2.2 ± 1.1 15.7 ± 3.0 4.1 ± 1.7 26.5 ± 3.6 3.8 ± 2.4 > 48 0 
AMB + ANI 9.6 ± 2.5 1.6 ± 2.1 14.5 ± 3.1 3.3 ± 3.7 31.1 ± 7.1 11.2 ± 4.6 >48 0 
VOR + CAS 3.5 ± 0.8 2.7 ± 1.4 9.9 ± 2.2 5.8 ± 3.2 39.7 ± 14.4 7.4 ± 5.4 >48 0 
VOR + ANI 6.8 ± 7.1 3.6 ± 3.3 26 ± 15.5 11.8 ± 5.7 45.0 ± 5.2 8.5 ± 9.0 >48 0 
A. terreus         
AMB + CAS 31.4 ± 12.5 12.2 ± 0.2 37.5 ± 14.8 >16.2 ± 1.9 >48 >14.7 ± 0.2 >48 >13.7±1.6 
AMB + ANI 20.5 ± 0.0 7.8 ± 1.8 24.4 ± 0.4 5.9 ± 2.5 32.4 ± 9.1 10.9 ± 9.9 47.6 ± 0.8 >7.5±1.9 
VOR + CAS 5.3 ± 1.8 3.5 ± 0.7 9.1 ± 1.1 2.3 ± 0.4 20.4 ± 3.9 7.6 ± 5.3 >48 0 
VOR + ANI 4.8 ± 0.4 3.0 ± 0.7 9.7 ± 6.4 2.9 ± 0.2 17.0 ± 6.5 4.1 ± 3.2 >48 0 
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Against the A. fumigatus strain tested a minor synergistic effect of amphotericin B combined 
with caspofungin was observed, with a delay of heat detection of 1.6 - 4.1 h, compared to the 
drug alone. A stronger synergistic effect was achieved when amphotericin B and 
anidulafungin were combined, which increased the delay to growth detection with up to 11.2 
h in comparison to amphotericin B alone at 0.5 x MIC. The improved activity of voriconazole 
in combination with an echinocandin was more pronounced. Figure 1 shows the activity of 
voriconazole and caspofungin, alone and in combination, against A. fumigatus by 
microcalorimetry and microscopy at 24 h and 48 h. The most active combination against A. 
fumigatus was voriconazole plus anidulafungin with an increase in heat inhibition of 11.8 ± 
5.7 h and 8.5 ± 9.0 h, at 0.25 x and 0.5 x MIC (MEC), respectively, as compared to 
voriconazole alone.  
A. terreus is intrinsically less susceptible to amphotericin B, exhibiting a MIC of >16 µg/ml 
as determined at 48 h by microscopy. When amphotericin B was combined with caspofungin 
or anidulafungin, a strong synergistic effect was observed with delay of heat production of 5.9 
- >16.2 h. Figure 2 shows the activity of amphotericin B and anidulafungin against A. terreus 
by microcalorimetry and microscopy. A clear reduction in microscopical growth and change 
in morphology was observed in the presence of the combination at all concentrations tested. A 
delay of heat detection of up to 10.9 ± 9.9 h was observed in the presence of the combination 
in comparison to amphotercin B alone. The addition of an echinocandin to voriconazole did 
only show a minor synergistic effect, with a delay of growth of 2.3 - 4.1 h, except for the 
combination voriconazole and caspofungin at 0.5 x MIC (MEC) that delayed the growth 
related heat-production by 7.6 ± 5.3 h. 
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Figure 1. Growth inhibition of A. fumigatus by voriconazole (A) and caspofungin (B) alone or in combination (C), as determined by microcalorimetry (upper panel) and 
microscopy at 24 h and 48 h (lower panel). The growth control (GC) is presented in duplicate. Antifungals were tested in combination at 0.125 x, 0.25 x, 0.5 x and 1 x MIC or 
MEC. Magnifications, x40. 
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Figure 2. Growth inhibition of A. terreus by amphotericin B (A) and anidulafungin (B) alone or in combination (C), as determined by microcalorimetry (upper panel) or 
microscopy at 24 h and 48 h (lower panel). The growth control (GC) is presented in duplicate. Antifungals were tested in combination at 0.125 x, 0.25 x, 0.5 x and 1 x MIC or 
MEC. Magnifications, x 40. 
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Discussion. 
 
In the present study, we demonstrated the potential of isothermal microcalorimetry for 
evaluation of antifungal combinations against Aspergillus spp. In contrast to the standard 
method for assessing antifungal combinations (i.e. checkerboard microbroth dilution assay), 
microcalorimetry allows real-time evaluation of antifungal activity. The result is not based on 
subjective visual examination, rendering the method particularly useful for susceptibility 
testing of molds, which often show heterogeneous growth characteristics. Due to the 
incomplete growth inhibition of molds by the echinocandins, two different endpoints are often 
used by the checkerboard assay. The endpoints, MIC or MIC-0 for optically clear and MEC or 
MIC-2 for a prominent growth reduction (6, 20), are read by visual inspection, which may be 
subjective and needs experienced personnel. Furthermore, the choice of the endpoint can 
influence whether a combination will show synergistic or only additive effect (5). 
Microcalorimetry has the advantage of testing echinocandins alone or in combination by 
measuring heat production instead of growth medium turbidity.  
In parallel to the microcalorimetric assay, the activity of antifungal combinations was 
investigated by microscopy and congruent changes in morphology and growth reduction were 
observed, as shown in Fig. 1 and 2. If similar results are obtained by two different methods, 
one can suppose that the combination could have a clinical importance. Due to the highly 
sensitive detection of growth by the microcalorimeter, the MIC determined by visual 
inspection did not completely inhibit heat-related growth production. Thus, the MIC was 
additionally determined by microscopy, which better correlated with the microcalorimetric 
data.  
In this proof-of-concept study, only two Aspergillus strains were included. Against the tested 
A. fumigatus strain, the addition of an echinocandin improved the activity of voriconazole 
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more than the activity of amphotericin B. Previous in vitro studies have reported both synergy 
and indifference when combining voriconazole with caspofungin [19] or anidulafungin [18]. 
An addition of anidulafungin to amphotericin B or voriconazole showed a stronger synergistic 
effect than the addition of caspofungin, which may be due to the stronger in vitro activity 
against non-germinated conidia observed with anidulafungin in comparison with other 
echinocandins (1). However, a more recent in vitro study only reported minor differences in 
activity of anidulafungin and caspofungin (16). Even though A. terreus is less frequently 
causing aspergillosis than A. fumigatus and A. flavus, this species was chosen due to its 
intrinsically reduced susceptibility to amphotericin B (3). We observed an improved activity 
of amphotericin B in the presence of an echinocandin, whereas the activity of voriconazole 
was not considerably improved. A decrease in the MIC of amphotericin B in the presence of 
caspofungin has been previously described and could be explained by an increased 
penetration of amphotericin B due to the disturbed cell wall by caspofungin (2). The 
microcalorimetric curve additionally demonstrates a slower growth of A. terreus in 
comparison with A. fumigatus, which may also influence increased susceptibility to 
amphotericin B. Combinations of echinocandins with azoles or amphotericin B have shown 
positive results when tested in animal models and their lack of toxicity makes them attractive 
for combination therapy (10). However, clinical studies are needed to generate solid evidence-
based data supporting the use of combination therapy. 
In summary, an improved activity of both amphotericin B and voriconazole was observed 
when combined with an echinocandin, with variations depending on the antifungal and mold 
combination. This proof-of-concept study demonstrated the potential of isothermal 
microcalorimetry for real-time evaluation of antifungal combinations against Aspergillus spp., 
in combinations including particularly echinocandins. The assay merits further validation by 
testing of additional strains, other mold species and antifungal combinations. 
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Chapter 12. General conclusions and outlook. 
 
The importance of antifungal susceptibility testing is continuously increasing by the shift in 
mold epidemiology towards non-Aspergillus genera and the emergence and spread of resistant 
strains. Resistant strains do not always exhibit cross-resistance to all antifungals in the same 
group, as was shown for itraconazole-resistant A. fumigatus strains, remaining susceptible to 
other triazoles. Progress in the field of nucleic-acid sequencing, allowing fungal species 
identification, has provided new insights into the molecular taxonomy of molds. Several 
sibling species to A. fumigatus, such as A. lentulus, have been identified, exhibiting a reduced 
susceptibility to many antifungals. Among the emerging molds, such as the Mucorales, 
species identification revealed variability in susceptibility among the different genera, 
highlighting that the choice of appropriate antifungal therapy cannot be based on the fungal 
class but species identification and susceptibility testing is recommended.  
The utility of antifungal susceptibility testing is a controversial issue in clinical practice due to 
lack of well-established clinical breakpoints for molds. The unavailability of these 
breakpoints is mostly due to great variability of the host status, but may also be due to 
suboptimal performance of in vitro testing methods currently used in routine practice. The 
lack of appropriate tests is particularly evident for evaluation of antifungal combinations. 
Susceptibility test methods based on measurement of turbidity of the growth medium are 
challenged by heterogeneous hyphal growth and variation in growth rate of molds, rendering 
the visual test interpretation difficult.  
Isothermal microcalorimetry is commonly used for analysis of chemical and biochemical 
reactions, either consuming or producing energy. During the last decade, the utility and 
advantages of isothermal microcalorimetry for highly sensitive detection of microbial growth 
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was demonstrated for a range of microorganisms. In chapter 9 and 10, we evaluated the 
thermokinetic profiles of different mold species, including Aspergillus and non-Aspergillus 
spp., and were able to detect fungal growth of Aspergillus spp. and Mucorales in <5 h and in 7 
h and 17 h for Fusarium and Scedosporium spp., respectively, under defined conditions. As 
demonstrated in chapter 11, the sensitivity of the microcalorimeter for growth detection was 
more comparable to growth detected by microscopy than to macroscopically visual growth. 
Despite enabling rapid growth detection, microcalorimetry does not allow species 
identification, as the heat produced is an unspecific signal of all thermal processes taking 
place in the test ampoule. Nevertheless, the use of a selective media could allow 
differentiation between genera. In a clinical setting, microcalorimetry could offer a rapid 
discrimination between culture positivity and negativity of sputum or bronchoalveolar lavage 
fluid samples. 
In chapter 9 and 10, we demonstrated the potential of isothermal microcalorimetry, as a novel 
method for antifungal susceptibility testing of molds. Due to the complex life cycle of molds, 
microcalorimetry appears to be a suitable and precise approach for performing antifungal 
susceptibility testing, as the test interpretation is not based on subjective visual examination 
and the data is obtained continuously in real-time (as heat-flow curve). We demonstrated that 
amphotericin B, triazoles and echinocandins affected the growth-related heat production of 
Aspergillus spp. in different manners, depending on their fungistatic or fungicidal properties. 
The presence of amphotericin B or a triazole delayed the heat production in a concentration-
dependent manner and the minimal heat inhibition concentration (MHIC) was determined as 
the lowest concentration inhibiting 50% of the heat produced at 24 h, 48 h or 72 h, depending 
on species. Due to the different mechanisms of action echinocandins, the MHIC for this 
antifungal class was determined as the lowest concentration lowering the heat-flow peak with 
50%. For Aspergillus spp. (chapter 9), agreement within two 2-fold dilutions between MHIC 
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and MIC or MEC (determined by CLSI M38A) was 90% for amphotericin B, 100% for 
voriconazole, 90% for posaconazole and 70% for caspofungin. In order to validate our assay, 
azole-resistant A. fumigatus mutants were included. We further evaluated our assay for 
antifungal susceptibility testing of non-Aspergillus molds (chapter 10). As determined by 
microcalorimetry, amphotericin B was the most active agent against Mucorales (MHIC 0.06-
0.125 μg/mL) and Fusarium spp. (MHIC 1-4 μg/mL), whereas voriconazole was the most 
active agent against Scedosporium spp. (MHIC 0.25 to 8 μg/mL). Whereas interpretation of 
susceptibility data by the conventional microbroth dilution method is rather subjective and 
requires experienced personnel, microcalorimetry offers an objective approach for data 
interpretation, based on a delay of heat production or change of the calorimetric curve, related 
to the inhibition of growth (MIC) or change of growth mode (MEC), respectively.  
We compared our data with MIC and MEC values obtained by the standard method for 
antifungal testing and were able to correlate our results when using the same time of 
incubation. However, considering the advantage of real-time growth monitoring, the 
microcalorimetric assay could be further optimized for a rapid detection resistant isolates. 
Indeed, in a future study we will screen a strain collection of 50 azole-resistant A. fumigatus 
isolates, with the goal to establish a rapid and sensitive assay for detection of azole resistance, 
as was previously described for the differentiation between methicillin-susceptible and 
methicillin resistant S. aureus using the same methodology. 
In chapter 11, we evaluated the activity of four antifungal combinations against A. fumigatus 
and A. terreus by microcalorimetry. The standard in vitro method used for synergy testing of 
molds, the checkerboard microdilution method, has been criticized for the FIC index ranges 
used for interpretation, as a majority of combinations show indifference or additive effect. 
Based on real-time measurements, we were able to show that the addition of an echinocandin 
to amphotericin B or voriconazole, delayed the detection of growth-related heat production of 
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the tested Aspergillus spp. in comparison to the drug alone. The improved activity varied 
between the two echinocandins and fungal species tested. The great potential of 
microcalorimetry for antifungal synergy testing needs to be further explored by testing of 
additional strains, other mold species and antifungal combinations. 
For a future use of microcalorimetry in a clinical microbiological laboratory, several issues 
need to be considered. First, the currently used isothermal microcalorimeters are too 
expensive and need to be simplified and adapted to the test conditions needed for 
microbiological applications (e.g. a narrow temperature range) in order to lower the cost of 
the instrument. Second, the instrument needs to allow a semi- or fully automated processing 
of multiple samples enabling high-throughput testing. In order to meet these criteria, 
promising development in the field of calorimetric instrument includes the recent market 
entry of a 48-well plate isothermal microcalorimeter designed for biological assays 
(CalScreener, SymCel AB) and a high-throughput low-cost chip calorimeter (chipCAL, TTP 
Labtech Ltd). 
 
 
 
 
